One of the most common questions I see here: “Should I research semaglutide or tirzepatide?” Let’s break down what the published data actually shows.
Mechanism of Action
Semaglutide (GLP-1 agonist)
- Single target: GLP-1 receptor
- Slows gastric emptying
- Increases satiety signaling
- Reduces glucagon secretion
Tirzepatide (Dual GIP/GLP-1 agonist)
- Dual target: Both GIP and GLP-1 receptors
- GIP component may enhance insulin sensitivity
- Potentially different effect on energy expenditure
- Newer compound, less long-term data
Published Research Outcomes
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Avg weight reduction | 15-17% | 20-22% |
| Time to plateau | ~16-20 weeks | ~20-24 weeks |
| A1C reduction | 1.5-2.0% | 2.0-2.5% |
Data from STEP and SURMOUNT trial publications
Side Effect Profiles
Common to both:
- Nausea (especially during titration)
- Decreased appetite
- Injection site reactions
- GI disturbances
Notable differences:
- Some researchers report tirzepatide has slightly more GI effects initially
- Semaglutide appears to have more published safety data due to longer market presence
Cost Considerations (Research Grade)
Pricing varies significantly by source. Always verify purity with third-party COAs.
Discussion Questions:
- If you’ve researched both, what differences did you observe?
- Did you switch from one to the other? Why?
- How did side effects compare in your experience?
- Any observations on efficacy differences?
Let’s share data and help the community make informed research decisions! 
Disclaimer: This is for research discussion only. These are not approved for human use outside of prescription.